Ant Group Achieves 2022 Carbon Neutrality Across Its Operations for the Second Consecutive Year
According to figures certified by the China Environmental United Certification Center (“CEC”), Ant Group has once again achieved operational carbon neutrality (Scope 1 & 2) for the second consecutive year, following the company’s initial achievement in 2021. This marks another concrete step for Ant Group towards fulfilling its pledge made in March 2021 to achieve net zero carbon emissions across Scope 1, 2 & 3 by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420006073/en/
Through a combination of reduction, substitution and offset measures, Ant Group achieved carbon neutrality in Scope 1 & 2 in 2022. (Graphic: Business Wire)
The Greenhouse Gas Protocol (“Protocol”) classifies a company's Greenhouse Gas Emissions (“GHG”) into Scope 1, 2 and 3. Based on the Protocol, Ant Group, in its Carbon Neutrality Road Map, released in April 2021 , defined its GHG emissions scopes as follows:
- Scope 1: direct & fugitive emissions from the combustion of fossil fuel by the company’s owned or controlled sources.
- Scope 2: indirect emissions from the consumption of purchased energy, such as heating or cooling networks.
- Scope 3: indirect emissions which occur in the company's value chain, such as emissions from the use of leased data centers, employees’ business travel and their daily commute.
According to CEC certified figures, in 2022, after reductions and substitutions, Ant Group's greenhouse gas (GHG) emissions for Scope 1 & 2 totaled 21,087.93 tonnes of CO2e, which were fully offset by the company’s purchase of carbon credits from a Verified Carbon Standard (VCS) Project, namely the CECIC Gansu Yumen Changma No.3 Wind Farm Project (VCS Project No.728).
CEC certified figures indicate that Ant Group reduced a total of 68,665.35 tonnes of CO2e across Scope 1, 2 & 3 in 2022, up 81% from 37,909.87 tonnes in 2021. This is equivalent to taking more than 28,000 cars off the road each year, assuming each car is driven 12,000 kilometers per year at 0.203 kilogram of CO2e per kilometer. The CEC was an official service provider to the 2022 Winter Olympics, helping the Olympic Committee measure the effectiveness of its carbon reduction efforts.
This reduction was mainly due to the implementation of green computing technologies. These technologies reduced about 62,000 tonnes of CO2e, which accounted for more than 99% of all carbon emissions reduced in Scope 3 during 2022. This was a 110% improvement over the 30,000 tonnes of CO2e that green computing technologies reduced in 2021.
“At Ant Group, we believe a company’s commercial value creation should go hand in hand with social value creation,“ said Yijie Peng, Chief Sustainability Officer of Ant Group. “Technological innovations has always been an important pathway for us to achieve this goal. We are committed to reaching net zero carbon emissions by 2030 and will continue to explore innovative ways to help reduce our carbon footprint and that of the industry.”
Ant Group has been developing and adopting green computing technologies since 2019. These technologies include Green AI, a series of technologies such as elastic management, GPU memory pooling and virtualization, which make large-scale model training more efficient.
For example, ATorch, Ant Group's PyTorch extension library, can double the utilization rate of AI computing power in large GPU cluster configurations compared to Megatron-DeepSpeed, an opensource deep learning optimization software suite. The use of ATorch has led to energy efficiency gains and carbon emission reductions for AI model training operations, which the company uses to iterate its AI-based products and services for better customer experience.
Ant Group also uses other green computing technologies, such as online-offline hybrid deployment, cloud-native time-shared scheduling, AI-based auto scaling, and OceanBase enterprise-level distributed relational database to help improve energy efficiency of data centers.
In 2022, Ant Group joined the Low Carbon Patent Pledge and granted free patent access to its green computing technologies.
The CEC’s carbon neutrality certificate for Ant Group for the year 2022 is publicly available on the Information Platform for Carbon Neutrality, which is affiliated with the Environmental Development Center of China’s Ministry of Ecology and Environment.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420006073/en/
Contact information
Media Enquiries
Zhumei WANG
zhumei.wzm@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
